Novartis touts older cancer drug for MS in attack on Roche's Ocrevus
Novartis said on Wednesday that an older leukaemia drug it is re-purposing for multiple sclerosis halted disease activity in many patients during the first two years of injections as the Swiss drugmaker takes aim at Roche's lucrative Ocrevus infusion.
from Reuters: Health News https://reut.rs/2TDUshi
https://bit.ly/2zwRqiM
May 26, 2020
|
Labels:
health,
Reuters: Health News
|
This entry was posted on May 26, 2020
and is filed under
health
,
Reuters: Health News
.
You can follow any responses to this entry through
the RSS 2.0 feed.
or trackback from your own site.